Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

Lii Tzu Wu; Hwa Jen Wu; Jing Gung Chung; Yin Ching Chuang; Kuo Chen Cheng; Wen-Liang Yu

doi:10.1016/j.diagmicrobio.2005.09.005

Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

Lii Tzu Wu
, Hwa Jen Wu
, Jing Gung Chung
, Yin Ching Chuang
, Kuo Chen Cheng
, Wen-Liang Yu

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log₂ dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,

Original language	English
Pages (from-to)	89-94
Number of pages	6
Journal	Diagnostic Microbiology and Infectious Disease
Volume	54
Issue number	2
DOIs	https://doi.org/10.1016/j.diagmicrobio.2005.09.005
Publication status	Published - Feb 2006

Keywords

CTX-M
Proteus mirabilis
β-Lactamases

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2005.09.005

Cite this

@article{ca1022d8d72341cc812c5f9e2444c2ba,

title = "Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan",

abstract = "From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6\%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC, ",

keywords = "CTX-M, Proteus mirabilis, β-Lactamases",

author = "Wu, \{Lii Tzu\} and Wu, \{Hwa Jen\} and Chung, \{Jing Gung\} and Chuang, \{Yin Ching\} and Cheng, \{Kuo Chen\} and Wen-Liang Yu",

year = "2006",

month = feb,

doi = "10.1016/j.diagmicrobio.2005.09.005",

language = "English",

volume = "54",

pages = "89--94",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

AU - Wu, Lii Tzu

AU - Wu, Hwa Jen

AU - Chung, Jing Gung

AU - Chuang, Yin Ching

AU - Cheng, Kuo Chen

AU - Yu, Wen-Liang

PY - 2006/2

Y1 - 2006/2

N2 - From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,

AB - From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,

KW - CTX-M

KW - Proteus mirabilis

KW - β-Lactamases

UR - https://www.scopus.com/pages/publications/31744449484

UR - https://www.scopus.com/pages/publications/31744449484#tab=citedBy

U2 - 10.1016/j.diagmicrobio.2005.09.005

DO - 10.1016/j.diagmicrobio.2005.09.005

M3 - Article

C2 - 16406185

AN - SCOPUS:31744449484

SN - 0732-8893

VL - 54

SP - 89

EP - 94

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 2

ER -

Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this